Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 4
1968 2
1969 4
1970 3
1972 3
1973 3
1974 4
1975 3
1976 4
1977 9
1978 6
1979 6
1980 7
1981 7
1982 7
1983 3
1984 3
1985 3
1986 7
1987 3
1988 2
1989 8
1990 5
1991 8
1992 15
1993 4
1994 3
1995 10
1996 8
1997 7
1998 5
1999 2
2000 12
2001 9
2002 4
2003 2
2004 5
2005 3
2006 1
2007 4
2008 3
2009 2
2010 3
2011 4
2012 1
2013 6
2014 6
2015 4
2016 5
2017 5
2018 3
2019 2
2020 4
2021 3
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Results by year

Filters applied: . Clear all
Page 1
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA. Kamat AM, et al. Among authors: lamm dl. J Clin Oncol. 2016 Jun 1;34(16):1935-44. doi: 10.1200/JCO.2015.64.4070. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811532 Free PMC article. Review.
Editorial Comment.
Lamm DL. Lamm DL. J Urol. 2018 Jun;199(6):1451. doi: 10.1016/j.juro.2017.12.076. Epub 2018 Mar 12. J Urol. 2018. PMID: 29545189 No abstract available.
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Steinberg RL, et al. Among authors: lamm dl. J Urol. 2020 May;203(5):902-909. doi: 10.1097/JU.0000000000000688. Epub 2019 Dec 10. J Urol. 2020. PMID: 31821066
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.
Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, Clark W, Kroeger M, Dumbadze I, Chamie K, Kader AK, Curran D, Gutheil J, Kuan A, Yeung AW, Steinberg GD. Packiam VT, et al. Among authors: lamm dl. Urol Oncol. 2018 Oct;36(10):440-447. doi: 10.1016/j.urolonc.2017.07.005. Epub 2017 Jul 26. Urol Oncol. 2018. PMID: 28755959 Clinical Trial.
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, Kates MR, Bivalacqua TJ, Tran PT, Song DY, Baras AS, Matoso A, Choi W, Smith KN, Pardoll DM, Marchionni L, McGuire B, Grace Phelan M, Johnson BA 3rd, O'Neal T, McConkey DJ, Rose TL, Bjurlin M, Lim EA, Drake CG, McKiernan JM, Deutsch I, Anderson CB, Lamm DL, Geynisman DM, Plimack ER, Hallman MA, Horwitz EM, Al-Saleem E, Chen DYT, Greenberg RE, Kutikov A, Guo G, Masterson TA, Adra N, Kaimakliotis HZ. Hahn NM, et al. Among authors: lamm dl. Eur Urol. 2023 Jun;83(6):486-494. doi: 10.1016/j.eururo.2023.01.017. Epub 2023 Jan 28. Eur Urol. 2023. PMID: 36717286 Clinical Trial.
Editorial comment.
Lamm DL. Lamm DL. Urology. 2011 Oct;78(4):854-5. doi: 10.1016/j.urology.2011.05.059. Urology. 2011. PMID: 21982004 No abstract available.
Carcinoma in situ.
Lamm DL. Lamm DL. Urol Clin North Am. 1992 Aug;19(3):499-508. Urol Clin North Am. 1992. PMID: 1636234 Review.
Innovation in Bladder Cancer Immunotherapy.
Grossman HB, Lamm DL, Kamat AM, Keefe S, Taylor JA 3rd, Ingersoll MA. Grossman HB, et al. Among authors: lamm dl. J Immunother. 2016 Oct;39(8):291-7. doi: 10.1097/CJI.0000000000000130. J Immunother. 2016. PMID: 27428265 Review.
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, Campbell MT, Compérat E, Efstathiou JA, Grivas P, Gupta S, Kurtz NJ, Lamm D, Lerner SP, Li R, McConkey DJ, Palou Redorta J, Powles T, Psutka SP, Shore N, Steinberg GD, Sylvester R, Witjes JA, Galsky MD. Kamat AM, et al. Among authors: lamm d. J Clin Oncol. 2023 Dec 10;41(35):5437-5447. doi: 10.1200/JCO.23.00307. Epub 2023 Oct 4. J Clin Oncol. 2023. PMID: 37793077 Free PMC article.
Bacillus Calmette-Guerin immunotherapy.
Lamm DL. Lamm DL. J Urol. 1987 Aug;138(2):391-2. doi: 10.1016/s0022-5347(17)43158-2. J Urol. 1987. PMID: 3599262 No abstract available.
254 results